| Ytd | 47.73% | |
| 1y | 45.62% |
| Open | 102.44 | Prev Close | 102.70 | Low | 96.18 | High | 102.44 | Mkt Cap | 647.52M |
| Vol | 382.78K | Avg Vol | 223.30K | EPS | -2.20 | P/E | N/A | Forward P/E | -10.17 |
| Beta | 1.10 | Short Ratio | 0.15 | Inst. Own | 24.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 111.50 | 200-d Avg | 76.04 | 1yr Est | 27.33 |
MNPR News
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and
Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report)
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 f
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STU
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overw
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upg
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises t
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the a
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR)
The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN184
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises t
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR)
Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline fr
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan
WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Com
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the a
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Compan
Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopa
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins l
Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ma
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the a
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ra
Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
